MedTrace Logo

Tailored Sonidegib Schedule After Complete Response in BCC

NCT04806646 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2022-08-04

No results posted yet for this study

Summary

Adult patients with locally advanced BCC, not amenable to surgical treatment and who obtained a complete response (CR) to Hedgehog inhibitors are administered a tailored schedule of the study drug. The tailored schedule consists of a change in the time of drug assumption. It implements some weeks of assumption and some weeks of suspension of sonidegib rather than a continuous administration.

Conditions

  • Locally Advanced Basal Cell Carcinoma

Interventions

DRUG

Sonidegib

TS1: assumption 14 days on and 14 days off. TS2: assumption 7 days on and 21 days off.

Sponsors & Collaborators

  • Gruppo Oncologico del Nord-Ovest

    lead OTHER

Principal Investigators

  • Paolo Bossi, MD · Gono - ASST Spedali Civili Brescia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-12
Primary Completion
2024-01-12
Completion
2026-01-12

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04806646 on ClinicalTrials.gov